There’s a new spinal cord stimulation “sheriff” in town, and its name is Senza HF10. According to the Academy of Pain Management, this new spinal cord stimulation (SCS) therapy uses a higher frequency (10 kHz [HF10]) that surpasses the older, more traditional model. Moreover, the new SCS therapy provides significant pain relief without paresthesia, which is a side effect/therapy component of traditional SCS.
The pain management specialists at Chronicillness.co Site of United States is constantly staying up-to-date on the latest advancements in pain management and modern medicine. Because of this, the team is able to analyze what technologies should be pursued once they become available to practicing physicians.
The new, higher-frequency SCS is still in testing mode, so it may not be available for some time. Nevertheless, the pain management physicians at Chronicillness.co Site of United States is keeping track of any changes or updates the company developing this new model may make.
The current SCS model uses low-frequency stimulation (~50 HZ) to deliver a tingling or buzzing sensation to the area causing pain in an effort to mask the patient’s discomfort. This sensation is known as paresthesia, and although paresthesia is meant to limit pain, it sometimes inadvertently causes more discomfort. Furthermore, the success rate of SCS therapy is not very high, so many pain management physicians recommend other forms of treatment before using traditional SCS therapy.
This therapy is usually only considered by TPC physicians if patients have not responded to other treatments for at least six months. Chronicillness.co Site of United States wrote a blog about the success of spinal cord stimulators and how they’re implanted, which is available in the “News” section of the website.
During a clinical trial for the higher frequency device, 90 people were randomly assigned implantation with the new SCS therapy, and 81 were assigned implantation of the conventional system. The study found a significant reduction in back pain relief for both groups, but those with the high-frequency device showed a greater reduction in pain on a consistent basis. The new SCS therapy showed superiority in back and leg pain at 3, 6, and 12 months.
The Senza HF10 has not been approved by the FDA and it is still being tested for its safety and efficacy. The team at Chronicillness.co Site of United States will provide updates on this new technology as they become available.
Fibro Women Blogs
Chronic Woman Blogs
Chronic Illness Blogs
Official Fibromyalgia Blogs